Last updated: September 7, 2026
Avapritinib, marketed as Ayvakit by Blueprint Medicines, has shifted from a niche gastrointestinal stromal tumor treatment into a broader mastocytosis franchise. Its commercial trajectory depends on three factors: expansion in systemic mastocytosis, continued penetration of PDGFRA exon 18-mutant GIST, and the durability of its patent and regulatory exclusivity position.
Blueprint reported approximately $278 million in Ayvakit product revenue in 2023, compared with roughly $133 million in 2022. The increase reflected the U.S. launch of Ayvakit for advanced systemic mastocytosis and the May 2023 approval for indolent systemic mastocytosis. [1]
What is avapritinib approved to treat?
Avapritinib is an oral, selective tyrosine kinase inhibitor targeting KIT and PDGFRA mutations. The FDA-approved indications are:
| Indication |
FDA milestone |
Commercial relevance |
| Unresectable or metastatic GIST with PDGFRA exon 18 mutations, including D842V |
January 2020 |
Establishes the original commercial base |
| Adults with advanced systemic mastocytosis, including aggressive systemic mastocytosis and systemic mastocytosis with associated hematologic neoplasm |
February 2021 |
High-value specialty market |
| Adults with indolent systemic mastocytosis |
May 2023 |
Expands the addressable population materially |
Avapritinib is the first FDA-approved treatment specifically indicated for indolent systemic mastocytosis. The indication is based on reduction of mast-cell burden and improvement in disease-related symptoms. [2]
How large is the avapritinib market opportunity?
The largest growth opportunity is systemic mastocytosis rather than GIST.
Systemic mastocytosis
Systemic mastocytosis is a rare clonal mast-cell disorder that is frequently associated with the KIT D816V mutation. The market includes:
- Advanced systemic mastocytosis, where treatment is intended to reduce disease burden and improve survival-related outcomes.
- Indolent systemic mastocytosis, where symptom control and reduction of mast-cell burden are central treatment objectives.
- Patients who are diagnosed late or remain untreated because symptoms overlap with allergic, gastrointestinal, dermatologic, or hematologic conditions.
The 2023 indolent systemic mastocytosis approval expanded Ayvakit from a specialist oncology product into a broader rare-disease therapy. The commercial opportunity is supported by chronic treatment duration, high unmet need, and the absence of an equally targeted FDA-approved competitor for the same broad indication.
The principal market constraints are disease underdiagnosis, uneven referral to mastocytosis centers, payer management, and the need for molecular or specialist confirmation.
PDGFRA-mutant GIST
Avapritinib has a differentiated position in GIST with PDGFRA exon 18 mutations, particularly the D842V mutation. These tumors are generally resistant to standard first-line KIT inhibitors such as imatinib.
The competitive sequence includes:
| Treatment |
Primary role in GIST |
Relationship to avapritinib |
| Imatinib |
Standard first-line therapy for most KIT-driven GIST |
Competes outside avapritinib’s strongest molecular niche |
| Sunitinib |
Second-line treatment |
Later-line alternative |
| Regorafenib |
Third-line treatment |
Later-line alternative |
| Ripretinib |
Fourth-line treatment and broader KIT/PDGFRA activity |
Competes in later-line disease |
| Avapritinib |
PDGFRA exon 18-mutant GIST, including D842V |
Molecularly differentiated treatment |
Avapritinib’s GIST opportunity is smaller than the overall GIST market but has a strong product-market fit because PDGFRA D842V disease has historically been poorly responsive to approved kinase inhibitors.
What is the financial trajectory for Ayvakit?
Ayvakit revenue has grown rapidly since launch, with acceleration after the systemic mastocytosis approvals.
| Fiscal year |
Ayvakit product revenue |
Key driver |
| 2021 |
Approximately $58 million |
Early GIST commercialization |
| 2022 |
Approximately $133 million |
GIST growth and initial advanced systemic mastocytosis uptake |
| 2023 |
Approximately $278 million |
Advanced and indolent systemic mastocytosis expansion |
| 2024 outlook available during 2024 |
Approximately $360 million to $380 million expected by Blueprint |
Continued mastocytosis penetration and prescriber expansion |
The 2022-to-2023 increase was approximately 109%. Growth at that rate was unlikely to persist indefinitely because the product was moving from early launch adoption toward a larger but more mature specialty commercial base. The key financial question was whether systemic mastocytosis could produce sustained annual growth after the initial launch surge.
Blueprint’s revenue mix was becoming increasingly concentrated in Ayvakit. That concentration improves operating leverage if sales continue to scale, but it also increases exposure to:
- Reimbursement restrictions
- Treatment discontinuation
- Label-related safety monitoring
- Competitive entry
- Pricing pressure
- Delays in diagnosing systemic mastocytosis
Which factors are driving avapritinib sales?
Indication expansion
The indolent systemic mastocytosis approval created the largest incremental growth opportunity. Unlike advanced systemic mastocytosis, indolent disease involves a larger pool of patients and can support long-term therapy.
Specialist prescribing
Treatment is concentrated among hematologists, oncologists, allergists, and mastocytosis referral centers. Blueprint’s commercial performance depends on identifying undiagnosed patients and moving them into specialist care.
Molecular differentiation
Avapritinib is highly differentiated in PDGFRA exon 18-mutant GIST and KIT-driven mastocytosis. This supports premium pricing and reduces direct substitution risk in biomarker-defined patients.
Chronic treatment duration
Patients with systemic mastocytosis may remain on therapy for extended periods if symptoms and disease burden improve. Chronic use can raise annual revenue per treated patient, although tolerability and payer authorization determine persistence.
International commercialization
Blueprint has used regional partnerships and licensing arrangements to expand access outside the United States. Zai Lab has been associated with commercialization rights for avapritinib in Greater China and selected Asian markets. Regional economics can produce milestone and royalty income, but they generally provide less control and lower revenue capture than direct U.S. commercialization. [3]
How strong is the competitive position of avapritinib?
Avapritinib has its strongest competitive position in two areas:
- PDGFRA exon 18-mutant GIST, particularly D842V disease.
- Systemic mastocytosis requiring a targeted KIT-directed treatment.
Its position is weaker where physicians prioritize tolerability, symptom-specific therapy, or established treatment experience.
Advanced systemic mastocytosis competition
Midostaurin is the principal approved targeted competitor in advanced systemic mastocytosis. It has broader kinase activity and an established treatment history. Avapritinib is more selective for KIT D816V and has a differentiated efficacy profile, but safety considerations, including cognitive effects and intracranial bleeding risk, can influence treatment selection. [2, 4]
Indolent systemic mastocytosis competition
The competitive environment includes:
- Symptom-directed therapies
- H1 and H2 antihistamines
- Leukotriene modifiers
- Cromolyn
- Omalizumab in selected patients
- Midostaurin or other off-label systemic approaches
- New targeted therapies under development
Avapritinib’s advantage is that it addresses mast-cell burden rather than only individual symptoms. Its disadvantage is that chronic safety management and cost may limit use in patients with moderate symptoms.
What are the main regulatory and safety risks?
The most important safety issues include cognitive effects, intracranial hemorrhage risk, edema, nausea, diarrhea, cytopenias, and other adverse events described in the FDA prescribing information. The risk-benefit assessment differs by indication.
In advanced disease, physicians may accept greater toxicity in exchange for disease control. In indolent disease, where patients may live for many years and symptoms vary widely, tolerability and quality of life carry greater weight.
This distinction creates a commercial risk: the larger indolent systemic mastocytosis population may have lower treatment urgency and higher sensitivity to adverse events than the advanced-disease population.
When does avapritinib lose exclusivity?
Avapritinib has patent protection covering the active compound, pharmaceutical compositions, treatment methods, and potentially specific uses or formulations. The practical loss-of-exclusivity date depends on the complete U.S. Orange Book listing, patent-term adjustments, pediatric exclusivity, regulatory exclusivity, and the scope of any generic or 505(b)(2) challenge.
The key exclusivity categories are:
| Exclusivity type |
Relevance |
| New chemical entity exclusivity |
The initial FDA approval provided five years of NCE exclusivity |
| Orphan-drug exclusivity |
Relevant to rare GIST and systemic mastocytosis indications |
| Method-of-use patents |
May protect approved uses after compound protection expires |
| Composition and formulation patents |
May restrict alternative dosage forms or formulations |
| Pediatric exclusivity |
Could add six months if granted for qualifying studies |
Because Ayvakit has several indications approved at different times, exclusivity is not a single date. Later approvals can create separate regulatory-exclusivity periods, while patent claims may cover more than one indication.
A generic company could challenge listed patents through an abbreviated new drug application and Paragraph IV certification. A 505(b)(2) applicant could pursue a modified formulation or dosing approach while challenging or designing around selected claims.
What generic entry risks exist?
Near-term generic risk is limited by the product’s rare-disease positioning, specialist prescribing base, and likely patent layering. Longer-term risk is more significant because oral small molecules are legally and technically easier to copy than biologics.
Potential entry strategies include:
- A conventional generic capsule or tablet after relevant patents expire.
- A 505(b)(2) product with a modified dosage form or dosing regimen.
- A product targeting the GIST indication first, where treatment is biomarker-defined.
- A product seeking a narrower label to avoid method-of-use claims.
- International entry before U.S. patent expiry.
The commercial impact of generic entry would depend on whether the generic label includes systemic mastocytosis, GIST, or both. A narrow GIST label would initially address a smaller market than a product able to compete across the mastocytosis franchise.
What manufacturing and intellectual-property barriers protect avapritinib?
Avapritinib is an orally administered small molecule, so manufacturing barriers are lower than for complex biologics. The main barriers are:
- Control of active pharmaceutical ingredient quality
- Reproducible tablet or capsule manufacture
- Bioequivalence
- Stability and impurity control
- Regulatory documentation
- Patent claims covering compound, salts, polymorphs, formulations, or dosing
- Specialized commercial distribution for rare-disease patients
The strongest protection is likely to come from compound and method-of-use claims rather than manufacturing complexity. Patent strength is highest where claims cover the core molecule and clinically important indications. Formulation claims are more vulnerable to design-around strategies unless they provide a meaningful pharmacokinetic or clinical advantage.
What litigation and settlement risks affect avapritinib?
The principal legal risk is a future Paragraph IV challenge to Orange Book-listed patents. A challenge could trigger a 30-month stay of FDA approval for the relevant ANDA, subject to statutory conditions and court outcomes.
Potential litigation issues include:
- Validity of compound claims
- Obviousness of avapritinib in light of earlier KIT or PDGFRA inhibitors
- Written-description and enablement challenges
- Infringement of method-of-use claims
- Patent-term calculations
- Carve-outs for GIST or systemic mastocytosis indications
- Settlement terms governing an authorized generic or launch date
No widely reported, market-defining U.S. generic settlement had altered Ayvakit’s commercial outlook through the 2023 reporting period. The absence of a public settlement does not eliminate future challenge risk.
How does avapritinib compare with competing mastocytosis drugs?
| Attribute |
Avapritinib |
Midostaurin |
Symptom-directed therapy |
| Target |
KIT, including KIT D816V |
Multikinase inhibitor including KIT |
Usually no direct disease target |
| Advanced systemic mastocytosis |
Approved |
Approved |
Supportive role |
| Indolent systemic mastocytosis |
Approved in the U.S. |
Not broadly approved for this indication |
Common background treatment |
| PDGFRA-mutant GIST |
Strongest targeted role |
Not a leading option |
Not relevant |
| Treatment objective |
Reduce mast-cell burden and symptoms |
Disease control in advanced disease |
Control individual symptoms |
| Commercial differentiation |
High in biomarker-defined disease |
Established competitor |
Low cost and broad use |
| Key limitation |
Safety, monitoring, and price |
Tolerability and broader kinase effects |
Does not directly reduce disease burden |
What is the investment and revenue exposure?
Blueprint’s financial exposure to Ayvakit is high because the product is the company’s primary commercial engine. That creates operating leverage: sustained growth can support margin expansion and reduce dependence on external financing. It also creates concentration risk if sales fall below expectations.
The principal upside drivers are:
- Continued growth in indolent systemic mastocytosis
- Increased diagnosis of systemic mastocytosis
- Long treatment duration
- Expansion outside the United States
- Stronger adoption in earlier lines of therapy
- Label expansion or supportive clinical data
The principal downside drivers are:
- Slower diagnosis and referral
- Safety-related discontinuation
- Payer restrictions
- Competition from newer KIT inhibitors
- Lower-than-expected persistence in indolent disease
- Patent litigation or earlier generic entry
- Revenue concentration in one product
What is the outlook for avapritinib?
Avapritinib’s commercial outlook is stronger than its original GIST-only profile. Systemic mastocytosis has converted Ayvakit into a multi-indication rare-disease franchise, with the largest growth potential in indolent disease.
The product’s growth rate should moderate from the 2023 launch expansion as the treated population increases and the market becomes more penetrated. The central commercial test is whether Blueprint can convert a newly diagnosed, heterogeneous indolent systemic mastocytosis population into a durable chronic-treatment base while maintaining safety and reimbursement access.
Key Takeaways
- Ayvakit is the commercial name for avapritinib, developed and marketed by Blueprint Medicines.
- The product is approved for PDGFRA exon 18-mutant GIST, advanced systemic mastocytosis, and indolent systemic mastocytosis.
- Ayvakit revenue increased from approximately $133 million in 2022 to approximately $278 million in 2023.
- Indolent systemic mastocytosis is the main expansion market.
- Midostaurin is the leading targeted competitor in advanced systemic mastocytosis.
- Avapritinib has its strongest differentiation in KIT D816V disease and PDGFRA D842V GIST.
- Generic risk is likely to emerge through patent challenges to compound, formulation, and method-of-use claims.
- Blueprint’s financial performance is highly dependent on Ayvakit sales.
- Long-term value depends on diagnosis rates, treatment persistence, tolerability, pricing, and patent duration.
FAQs
Is avapritinib a blockbuster drug?
Ayvakit had not reached the traditional $1 billion annual-sales threshold in the 2023 reporting period. Its revenue trajectory was consistent with a high-growth specialty product, with approximately $278 million in 2023 product sales.
Is avapritinib better than midostaurin?
The answer depends on indication, disease burden, prior treatment, tolerability, and physician judgment. Avapritinib has a more selective KIT-directed profile, while midostaurin has longer commercial experience in advanced systemic mastocytosis.
Can avapritinib be used for GIST without a PDGFRA mutation?
Its strongest approved GIST role is in PDGFRA exon 18-mutant disease, especially D842V. Use in other molecular subsets depends on the approved label, clinical evidence, and physician assessment.
Does avapritinib cure systemic mastocytosis?
Avapritinib is a disease-control treatment. It can reduce mast-cell burden and improve symptoms, but it is not generally described as a cure for systemic mastocytosis.
What company owns avapritinib?
Blueprint Medicines owns and commercializes avapritinib in the United States. Regional partners may hold commercialization or licensing rights in selected international markets.
References
-
Blueprint Medicines Corporation. (2024). 2023 annual report on Form 10-K. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Ayvakit (avapritinib) prescribing information. FDA.
-
Blueprint Medicines Corporation. (2023). Corporate and financial reports concerning Ayvakit commercialization and regional collaborations. Blueprint Medicines.
-
U.S. Food and Drug Administration. (2021). FDA approves avapritinib for advanced systemic mastocytosis. FDA.
